Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.66 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971349 | 0.86 | SCD (0.49) | SCDTGM2ALDH1A1LMNAKLKB1 | |
| SCHEMBL2177885 | 0.85 | SCD (0.48) | SCDTGM2ALDH1A1LMNAHPGD | |
| SCHEMBL1967602 | 0.83 | SCD (0.46) | SCDCA5ATGM2ALDH1A1LMNA | |
| SCHEMBL1967601 | 0.83 | SCD (0.46) | SCDCA5ATGM2ALDH1A1LMNA | |
| SCHEMBL2176792 | 0.83 | SCD (0.49) | SCDTGM2ALDH1A1LMNAHPGD | |
| SCHEMBL16798626 | 0.82 | CYP3A4 (0.60) | SCDCA5ATGM2ALDH1A1LMNA | |
| SCHEMBL9857993 | 0.80 | ALDH1A1 (0.63) | SCDCA5ATGM2ALDH1A1LMNA | |
| SCHEMBL1965913 | 0.80 | ALDH1A1 (0.70) | SCDALDH1A1LMNANOTUMHPGD | |
| SCHEMBL10666003 | 0.79 | SCD (0.58) | SCDCA5ATGM2ALDH1A1LMNA | |
| SCHEMBL27854173 | 0.79 | SCD (0.61) | SCDCA5ATGM2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2334666-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Canada Inc. (CA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010025553-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | SCD 1/4885CA5A 1025/4885TGM2 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.